

Cumulative Author index

Volumes 61–64 (2001)

- Aalto-Setälä, T. 62, 175
 Abraham, H.D. 63, 277
 Abrams, K. 64, 219
 Acosta, T. 63, 69
 Adelson, M. 61, 191
 Adler, M.W. 62, 109
 Alpan, G. 63, 97
 Alterman, A.I. 61, 145, 271
 Alterman, A.I. 62, 19
 Alterman, A.I. 63, 69
 Alvarez, A.I. 64, 27
 Alvarez, F.J. 64, 19
 Amass, L. 61, 173
 Andrzejewski, M.E. 63, 179
 Antelman, S.M. 61, 3
 Anthony, J.C. 63, 245
 Anthony, J.C. 64, 123
 Anttila, T. 62, 175
 Arfken, C.L. 61, 287
 Arseneault, J.R. 64, 299
 Ator, N.A. 61, 55, 69
 Avants, S.K. 61, 35
 Averill, P. 63, 207
- Babb, D.A. 63, 131
 Backmund, M. 64, 173
 Badger, G.J. 64, 111
 Balldin, J. 63, 263
 Balster, R.L. 61, 1
 Balster, R.L. 63, 1
 Barbanoj, M.J. 62, 215
 Barrau, K. 61, 281
 Barrio, G. 63, 169
 Battle, F. 63, 187
 Battegay, M. 64, 105
 Bauer, G. 61, 307
 Bauer, G. 64, 251
 Bauer, L.O. 63, 87
 Baumann, P. 61, 47
 Bayer, B.M. 62, 141
 Bein, E. 61, 105
 Ben-Abdallah, A. 61, 223
 Berggren, U. 63, 263
 Bernal, S.A. 63, 215
 Bickel, W.K. 61, 249
 Bickel, W.K. 64, 111
 Bigelow, G.E. 64, 271
 Billaud, J.-N. 62, 125
 Billet, O. 62, 125
- Bleich, A. 61, 191
 Bluthenthal, R.N. 62, 225
 Booth, R.E. 64, 165
 Bourquin, M. 61, 47
 Bovasso, G.B. 62, 19
 Bravo, M.J. 63, 169
 Breiter, H. 61, 163
 Breslau, N. 64, 1
 Brower, K.J. 61, 23
 Brown, S. 63, 131
 Bucher, H.C. 64, 105
- Cabral de Oliveira, C. 64, 27
 Cacciola, J.S. 61, 145, 271
 Cami, J. 64, 285
 Canet, J. 63, 117
 Canino, G. 63, 229
 Carmen del Rio, M. 64, 19
 Carpenter, K.M. 63, 51
 Carpenter, M.J. 62, 191
 Carter, K.M. 64, 299
 Casas, M. 63, 187
 Cascio, A. 63, 117
 Celentano, D. 61, 113
 Celentano, D.D. 61, 315
 Celentano, D.D. 62, 195
 Celentano, D.D. 64, 55
 Chantarujikapong, S.I. 61, 95
 Chao, C.C. 62, 149
 Charuvastra, V.C. 63, 139
 Chung, S.-e. 64, 55
 Chutuape, M.A. 61, 137
 Chutuape, M.A. 62, 69
 Clark, D.B. 61, 3
 Clarke, J. 61, 211
 Cnaan, A. 63, 69
 Cohn, S. 61, 315
 Coiro, V. 61, 217
 Colón, H.M. 63, 229
 Compton, P. 63, 139
 Compton, W.M. 61, 223
 Cone, E.J. 63, 97
 Connor, J.P. 61, 129
 Coover, M.D. 62, 205
 Copeland, A.L. 62, 91
 Cornish, J. 63, 69
 Cornish, J.W. 61, 183
 Cornish, J.W. 62, 1
 Cottler, L.B. 61, 223
- Coviello, D.M. 61, 145
 Craft, R.M. 63, 215
 Crosby, J. 64, 203
 Cross, J.C. 64, 191
 Cross, S.I. 61, 113
 Crowley, T.J. 61, 237
 Crum, R.M. 62, 195
- D'Ambra, M.N. 61, 163
 Darke, S. 62, 77
 Daunais, J.B. 61, 15
 Davies, H.M.L. 61, 15
 Davies, M. 64, 233
 Davis, W.R. 64, 191
 Dawes, M.A. 61, 3
 Degenhardt, L. 64, 319
 Déglon, J.-J. 61, 47
 Déglon, J.-J. 62, 97
 De La Fuente, L. 63, 169
 de la Torre, R. 64, 285
 Dhillon, A.S. 63, 199
 Di Marino, M.E. 64, 35
 Dixon, J. 64, 337
 Djeddar, S. 61, 281
 Dominguez, G. 62, 157
 Donahoe, R.M. 62, 109, 131
 Downey, K.K. 61, 287
 Dunn, J. 63, 79
 Duro, P. 63, 187
- Eap, C.B. 61, 47
 Ehrman, R.N. 61, 183
 Ehrman, R.N. 62, 1
 Eichenlaub, D. 64, 173
 Eisen, S.A. 61, 95
 Eisenstein, T.K. 62, 111
 Elman, I. 61, 163
 Eriksson, M. 63, 263
 Evans, S.M. 64, 271
- Faggiano, F. 64, 329
 Fahlke, C. 63, 263
 Farré, M. 64, 285
 Fendrich, M. 62, 239
 Ferrando, A. 64, 27
 Ferri, C.P. 63, 79
 Fischman, M.W. 64, 271
 Foltin, R.W. 64, 63, 271
 France, C.P. 63, 39

- Frederick-Osborne, S.L. 63, 269
 Freeman, W.M. 61, 15
 Friedmann, P.D. 64, 47
 Fudala, P.J. 61, 183
- Galen, L.W. 61, 23
 Galen, L.W. 62, 205
 Galloway, G.P. 63, 269
 Garcia, L. 63, 117
 Gariti, P. 63, 69
 Gastfriend, D.R. 61, 163
 Gekker, G. 62, 149
 Gekker, G. 64, 257
 Gelkopf, M. 61, 191
 Geninatti, S. 64, 329
 Gerak, L.R. 63, 39
 Gerostamoulos, J. 61, 123
 Gerra, G. 64, 63
 Giancola, P. 61, 3
 Giedd, J.N. 62, 49
 Gillespie, B.W. 61, 23
 Gilman, S.E. 63, 277
 Gioia, L. 61, 15
 Gitchell, J.G. 64, 35
 Glantz, M.D. 62, 57
 Glautier, S. 64, 337
 Glennon, R.A. 64, 203
 Glowa, J.R. 62, 41
 Gmel, G. 64, 151
 Gogineni, A. 62, 225
 Gogineni, A. 64, 47
 Goldberg, J. 61, 95
 Golden, A.S. 63, 97
 Gorgerat, S. 64, 203
 Gossop, M. 62, 255
 Goto, K. 64, 133
 Gottschalk, C. 62, 49
 Gough, R. 64, 203
 Grabowski, J. 63, 207
 Greenwood, G.L. 61, 105
 Griffiths, P. 64, 9
 Griffiths, R.R. 61, 69
 Gross, A. 64, 111
 Grupp, L. 61, 35
 Gupman, A.E. 61, 261
 Gupman, A.E. 62, 57
 Gyr, N. 64, 105
- Hall, S.K. 61, 237
 Hall, W. 62, 163
 Hall, W. 63, 147
 Hall, W. 64, 319
 Hameedi, F. 63, 155
 Haney, M. 64, 63
 Harris, D.S. 61, 85
 Harris, L.S. 63, 39
 Hart, S.L. 61, 15
 Hartz, D.T. 63, 269
 Hasin, D.S. 63, 51
 Hatsukami, D.K. 63, 131
 Hatzimanolis, J. 64, 363
- Haug, N. 61, 297
 Haug, N.A. 63, 97
 Hayward, R. 61, 191
 H. Drummer, O. 61, 123
 Heeb, J.-L. 64, 151
 Hein, N.D. 64, 299
 Helmus, T.C. 61, 287
 Henderson, M.J. 61, 287
 Henderson, M.J. 62, 205
 Hernández, C. 64, 285
 Höfler, M. 64, 347
 Holtzman, S.G. 62, 83
 Hönigschnabl, S. 61, 307
 Hönigschnabl, S. 64, 251
 Hoover, D.R. 64, 55
 Howard, M.O. 61, 223
 Huang, F.-Y. 64, 233
 Hudson, A.L. 64, 203
 Huggins, G.R. 63, 97
 Hughes, J.R. 62, 191
 Hung, Y.-Y. 64, 181
 Hunkeler, E.M. 64, 181
 Hu, S. 62, 149
 Husbands, S.M. 64, 203
 Hu, T.-w. 64, 181
- Iguchi, M.Y. 63, 179
 Ikemoto, S. 64, 133
 Ippolito, R. 64, 329
 Ishiguro, T. 64, 133
- Jacobs, E.A. 64, 111
 Jacobsen, L.K. 62, 49
 Jansson, L.M. 63, 97
 Jasinski, D.R. 63, 97
 John, D. 64, 165
 Johnson, B.D. 64, 191
 Johnson, E.O. 61, 261
 Johnson, E.O. 64, 1
 Johnson, R.E. 63, 97
 Jones, H.E. 61, 297
 Jones, H.E. 63, 97
 Jones, R.T. 61, 85
 Joyce, A. 62, 157
 Juday, T. 61, 195
- Kaff, A. 64, 251
 Kaff, G. 61, 307
 Kamali, F. 64, 265
 Kamien, J.B. 61, 173
 Kaminski, B.J. 61, 69
 Kampman, K.M. 63, 69
 Kandel, D.B. 64, 233
 Kane, M. 61, 163
 Katz, E.C. 61, 137
 Kautz, M.A. 61, 69
 Kaye, S. 62, 77
 Ketelsen, D. 62, 131
 Kirby, K.C. 63, 179
 Kissin, W.B. 63, 97
 Kleber, H.D. 61, 195
- Knowlton, A.R. 64, 55
 Koppenhaver, J.M. 62, 19
 Kopstein, A.N. 62, 195
 Kosten, T. 63, 253
 Kosten, T.R. 62, 49
 Kosten, T.R. 63, 155
 Krause, S. 61, 163
 Kreek, M.J. 62, 49
 Kuhar, M.J. 62, 157
 Kushner, M. 64, 219
 Kwiatkowski, C.F. 64, 165
- Labouvie, E. 62, 231
 Ladewig, D. 62, 97
 Ladewig, D. 64, 105
 Lagier, G. 61, 281
 Lambert, H. 61, 281
 Lantz, M.E. 63, 97
 Laranjeira, R. 62, 231
 Laranjeira, R. 63, 79
 László, L. 61, 155
 Latkin, C.A. 64, 55, 97
 Le Sage, M.G. 62, 41
 Lester, B.M. 63, 97
 Levin, F.R. 64, 271
 Lew, C. 63, 169
 Lewis, J.W. 64, 203
 Liberty, H.J. 64, 191
 Lichtman, A.H. 63, 107
 Lieb, R. 64, 347
 Liguori, A. 63, 123
 Lin, E. 61, 85
 Ling, W. 63, 139
 Lisdahl Medina, K. 64, 219
 Livoti, S. 61, 47
 Livoti, S. 62, 97
 Lokensgard, J.R. 64, 257
 Longshore, D. 62, 225
 Lönnqvist, J. 62, 175
 Luce, D. 63, 69
 Lukas, S.E. 64, 143
 Lykouras, L. 64, 363
 Lyles, C.M. 61, 113
 Lynch, K.G. 64, 75
 Lynskey, M. 64, 319
 Lyons, M.J. 61, 95
- Maany, I. 61, 183
 Macenski, M.J. 64, 243
 Madden, J.J. 62, 131
 Maksad, J. 61, 211
 Mantle, D. 63, 199
 Margolin, A. 61, 35
 Markianos, M. 64, 363
 Mark, T.L. 61, 195
 Márquez, M. 63, 117
 Marsden, J. 62, 255
 Martin, B.R. 63, 107
 Martin, J.-L. 61, 47
 Martin, S.S. 62, 195
 Marttunen, M. 62, 175

- Mas, M. 64, 285
 McCance-Katz, F.E. 63, 155
 McCarthy, L. 62, 111
 McCaul, M.E. 62, 9
 McKay, J.R. 61, 145, 271
 McKay, J.R. 62, 19
 Mellon, R.D. 62, 141
 Mendelson, J. 61, 85
 Menoyo, E. 64, 285
 Meyer, K. 64, 173
 Mezzich, A. 61, 3
 Micallef, J. 61, 281
 Mikulich, S.K. 61, 173, 237
 Miles, D.R. 61, 261
 Miles, D.R. 62, 57
 Mitola, B. 64, 329
 Moeller, F.G. 63, 207
 Moore, R.D. 62, 9
 Morral, A.R. 63, 179
 Morris, R. 61, 163
 Moss, H.B. 64, 75
 Moussas, G. 64, 363
 Muller, E. 63, 69
 Müller, F. 61, 155
 Mulvaney, F. 63, 69
 Mulvaney, F.D. 61, 271
 Mulvaney, F.D. 62, 19
 Muñoz, A. 61, 315
 Murray, K.S. 64, 309
- Nader, M.A. 63, 39
 Naef, M.R. 64, 105
 Nagy, J. 61, 155
 Nelson, K.E. 61, 113
 Newbury-Birch, D. 64, 265
 Newlin, D.B. 61, 261
 Newlin, D.B. 62, 57
 Nicholson, K.L. 63, 1
 Nishijima, K. 64, 133
 Nutt, D.J. 64, 203
- O'Brien, C. 63, 69
 O'Brien, C.P. 61, 183
 O'Brien, J. 64, 337
 Ogden, B.A. 64, 299
 Oliveto, A. 63, 155
 Orozco, S. 64, 143
 Ortiz, M. 63, 117
 Osmond, D.H. 61, 105
- Page-Shafer, K. 61, 105
 Paice, A. 63, 199
 Palmer, T.N. 63, 199
 Pandina, R. 62, 231
 Patrick, G.A. 63, 39
 Paty, J.A. 64, 35
 Paul, J. 61, 105
 Pérez de los Cobos, J. 63, 187
 Peterson, P.K. 62, 149
 Peterson, P.K. 64, 257
 Peters, T.J. 63, 199
- Petitjean, S. 62, 97
 Petrakis, I. 63, 155
 Petry, N.M. 62, 31
 Petry, N.M. 63, 29
 Petry, N.M. 64, 111
 Pfister, H. 64, 347
 Pfudl, S. 64, 251
 Phillips, T.R. 62, 125
 Pickens, R.W. 61, 261
 Pickens, R.W. 62, 57
 Pilowsky, D.J. 61, 113
 Pinsky, I. 62, 231
 Poikolainen, K. 62, 175
 Poklis, A. 63, 107
 Poklis, J.L. 63, 107
 Poole, S. 63, 69
 Porrino, L.J. 61, 15
 Powell, K. 61, 47
 Powell, K.R. 62, 83
 Preedy, V.R. 63, 199
 Preston, K.L. 61, 261
 Price, R.K. 64, 309
 Prieto, J.G. 64, 27
- Ranaldi, R. 64, 209
 Rehm, J. 64, 151
 Rhoades, H.M. 63, 207
 Riba, J. 62, 215
 Ribalta, E. 63, 187
 Ricciardelli, L.A. 61, 129
 Rice, D.P. 64, 181
 Rice, K.C. 62, 41
 Riggs, R.L. 62, 191
 Rinder, H.M. 61, 35
 Risk, N.K. 64, 309
 Risser, D. 61, 307
 Risser, D. 64, 251
 Robbins, S.J. 61, 183
 Robbins, S.J. 62, 1
 Robinson, J.H. 63, 123
 Rodriguez-Fornells, A. 62, 215
 Rogers, T.J. 62, 111
 Rohay, J.M. 64, 35
 Rosenberg, M.F. 63, 245
 Rosenberg, M.F. 64, 123
 Rosenheck, R. 63, 253
 Roset, P.N. 64, 285
 Ross, J. 62, 77
 Rowlett, J.K. 61, 229
 Royuela, L. 63, 169
 Rutherford, M.J. 61, 145, 271
- Sanmarco, J.L. 61, 281
 Scherrer, J.F. 61, 95
 Schmitz, J.M. 63, 207
 Schneider, B. 61, 307
 Schuster, C.R. 61, 287
 Schütz, C.G. 64, 173
 Sebal, D. 61, 307
 Sebal, D. 64, 251
 Seguí, J. 63, 117
- Setaro, J.F. 61, 35
 Shelton, K.L. 64, 243
 Sheng, W.S. 62, 149
 Sherman, S.G. 64, 97
 Shiffman, S. 64, 35
 Siliquini, R. 64, 329
 Silverman, K. 61, 297
 Silverman, K. 62, 69
 Singha, A. 63, 155
 Sliker, J.K. 62, 111
 Smith, B.J. 61, 249
 Sobota, M. 64, 117
 Sofuoglu, M. 63, 131
 Soine, W.H. 64, 299
 Sonntag, H. 64, 347
 Sorensen, J.L. 62, 91
 Soriano, J. 61, 261
 Spagnoli, J. 61, 47
 Spitznagel, E.L. 64, 309
 Stafford, D. 62, 41
 Staikos, V. 61, 123
 Stall, R.D. 61, 105
 Stein, M. 62, 225
 Stein, M.D. 61, 211
 Stein, M.D. 64, 47, 117
 Stewart, D. 62, 255
 Stewart, D. 64, 9
 Stichenwirth, M. 61, 307
 Stichenwirth, M. 64, 251
 Stitzer, M. 61, 297
 Stitzer, M.L. 61, 137
 Stitzer, M.L. 62, 69
 Stohler, R. 62, 97
 Stotts, A.L. 63, 207
 Strassman, R.J. 62, 215
 Susman, E.J. 61, 3
 Svikis, D. 61, 297
 Svikis, D.S. 62, 9
 Svikis, D.S. 63, 97
 Swift, W. 63, 147
- Tarter, R.E. 61, 3
 Teesson, M. 63, 147
 Tejero, A. 63, 187
 Thirion, X. 61, 281
 Torrens, M. 63, 169
 Treacy, S. 62, 255
 True, W.R. 61, 95
 Trujols, J. 63, 187
 Tsuang, M. 61, 95
 Tuffy, L. 61, 163
 Tuulio-Henriksson, A. 62, 175
 Tyacke, R. 64, 203
- Uehlinger, C. 62, 97
 Umbrecht, A. 61, 261
 Upton, R.A. 61, 85
- van den Bree, M.B.M. 61, 261
 van den Bree, M.B.M. 62, 57
 Vanyukov, M.M. 61, 3

- Varner, K.J. 64, 299
Versino, E. 64, 329
Vescovi, P.P. 61, 217
Vila, L. 64, 27
Virgo, K.S. 64, 309
Vlahov, D. 61, 113, 315
Vlahov, D. 64, 55
Voces, J. 64, 27
Voight, A. 64, 219
Volpicelli, J.R. 63, 69
von Sydow, K. 64, 347
Vrana, K.E. 61, 15
Vycudilik, W. 61, 307

Waldvogel, D. 62, 97
Walker, D.J. 64, 85
Walshaw, D. 64, 265
Walsh, S.L. 64, 271

Wang, Z. 64, 209
Ward, A.S. 64, 63
Ward, K. 62, 19
Warner, L.A. 63, 229
Weerts, E.M. 61, 69
Weisner, C. 64, 181
Welm, S. 61, 85
Wetzel, M. 62, 111
Whaley, W.L. 62, 131
White, E.W. 61, 105
Whitmore, E.A. 61, 237
Wilkins, D.G. 63, 97
Williams, R.J. 61, 129
Wilson, D.M. 63, 107
Winger, G. 62, 181
Winger, G. 63, 39
Winstock, A.R. 64, 9
Wittchen, H.-U. 64, 347
Woods, J.H. 62, 181

Woods, J.H. 63, 39
Woody, G.E. 61, 195
Woolverton, W.L. 61, 229
Woolverton, W.L. 63, 39
Woolverton, W.L. 64, 209

Xian, H. 61, 95

Yohrling, G.J., IV 61, 15
Yoshino, T. 64, 133
Young, R.M.D. 61, 129
Yui, K. 64, 133
Yun Soo Kim, J. 62, 239

Zacny, J.P. 63, 23
Zacny, J.P. 64, 85
Zanis, D.A. 61, 145
Zinkernagel, C. 64, 105
Zucker, R.A. 61, 23

Cumulative Subject index

Volumes 61–64 (2001)

Absorption rate; Flunitrazepam; Pharmacokinetics; Rate of onset of effects; Abuse liability **64**, 285

Abuse; Buprenorphine; Buprenorphine-naloxone; Dosing regimen; Pharmacotherapy **61**, 173

Abuse; Cannabis; Cohort; Dependence; Gender; Longitudinal study; Use **64**, 347

Abuse liability; Flunitrazepam; Absorption rate; Pharmacokinetics; Rate of onset of effects **64**, 285

Abuse liability; Nitrous oxide; Subjective effects; Choice; Reinforcing effects; Inhalants; Human **64**, 85

Abuse potential; Benzodiazepine; Barbiturates; Pentobarbital; Drug discrimination; Panadiplon (U-78875, PNU-78875) **61**, 229

Abuse potential; Benzodiazepine; CL 284846; Dependence; Feeding; Triazolam; Zaleplon **61**, 69

Abuse potential; CL 284,846; Drug discrimination; Feeding; Flumazenil; Pharmacokinetics; Self-administration; Triazolam; Zaleplon; Zolpidem **61**, 55

Abuse potential; Cocaine; GBR 12909; Phentermine; Progressive ratio; Self-administration; Pharmacotherapy **62**, 41

Academic achievement; Adolescence; Cannabis; Coitus; Lack of interest **62**, 175

Accidents; Cannabis; Respiratory disease; Dependence; Adverse effects **62**, 163

ACE-inhibitors; Cocaine; Cardiovascular; Platelet activation; Methadone; Fosinopril **61**, 35

Acetaldehyde; Myopathy; Biochemical mechanisms; Protein synthesis; Myosin; Metabolism; RNA; Proteolysis; Nutrition; Malnutrition **63**, 199

ACTH; Anesthesia; Naltrexone; Cortisol; Craving; Withdrawal **61**, 163

Add health study; Genetic and environmental influences; Marijuana use; Sensation seeking; Risk taking **62**, 57

Addiction; Methadone; Enantiomer; Blood; Cytochrome P-450 **61**, 47

Administration route; Heroin; Dependence; SDS scale **63**, 169

Adolescence; Academic achievement; Cannabis; Coitus; Lack of interest **62**, 175

Adolescence; Alcohol; Culture; Dependence; Epidemiology **63**, 229

Adolescence; Liability; Puberty; Affective, cognitive, and behavioral dysregulation; Neuroadaptation; Substance use disorder **61**, 3

Adolescents; Alcohol use disorders; Disruptive behaviors **64**, 75

Adolescent; Sleep problems; Insomnia; Alcohol; Tobacco; Drug abuse **64**, 1

Adolescents; Sensation seeking; Cigarette use; Disinhibition; Marijuana use **62**, 195

Adverse effects; Cannabis; Accidents; Respiratory disease; Dependence **62**, 163

Affective, cognitive, and behavioral dysregulation; Liability; Puberty; Adolescence; Neuroadaptation; Substance use disorder **61**, 3

Age; Sequence of substance use; Drug users; Opiates; Heroin **64**, 105

Aggression; Epidemiology; Delinquent behavior; Conduct disorder; Substance-related disorders **63**, 245

Alcohol abuse; Drinking and driving; Alcohol consumption; Traffic accidents; Social problems **62**, 231

Alcohol abuse; Polydrug abuse; Behavioral economics **62**, 31

Alcohol; Adolescence; Culture; Dependence; Epidemiology **63**, 229

Alcohol; Adolescent; Sleep problems; Insomnia; Tobacco; Drug abuse **64**, 1

Alcohol; Caffeine; Automobile driving; Equilibrium; Psychomotor performance **63**, 123

Alcohol; Cannabis; Comorbidity; Drug use; Population; Tobacco **64**, 319

Alcohol challenge; Social phobia; Co-morbidity; Alcohol use; Laboratory stress **64**, 219

Alcohol consumption; Drinking and driving; Alcohol abuse; Traffic accidents; Social problems **62**, 231

- Alcohol dependence:** Alcohol withdrawal; NMDA receptor; Excitotoxicity; Primary cortical culture **61**, 155
- Alcohol dependence:** Genetic; Illicit drug dependence; Posttraumatic stress disorder; Twins; Veterans **61**, 95
- Alcohol dependence:** Panic disorder; Cultural factors; Major depression; Dysthymia **63**, 117
- Alcohol detoxification:** Dopamine receptor responsivity; Relapse prediction **64**, 363
- Alcohol expectancies:** Alcohol motives **62**, 205
- Alcoholic subtype:** Cluster analysis; DSM-IV alcohol dependence; Type I/II-Type A/B **63**, 51
- Alcoholism:** Depressive disorder; Comorbidity; Epidemiology **63**, 277
- Alcoholism:** Gamma-amino-butyric acid; Gamma-hydroxy-butyric acid; Growth hormone **61**, 217
- Alcohol:** Medical students; Pre-registration house officers; Illicit drugs; Stress **64**, 265
- Alcohol motives:** Alcohol expectancies **62**, 205
- Alcohol:** Negative reinforcement; Heavy drinkers **64**, 337
- Alcohol:** Prolactin; Fenfluramine; SSRI **63**, 263
- Alcohol use disorders:** Adolescents; Disruptive behaviors **64**, 75
- Alcohol Use Disorders Identification Test (AUDIT):** Frequency of drinking; Psychometric analysis; Switzerland; Confirmatory factor analysis **64**, 151
- Alcohol use:** HMO alcohol costs; Drinking patterns and costs; U-shaped drinking curve **64**, 181
- Alcohol use:** Social phobia; Co-morbidity; Alcohol challenge; Laboratory stress **64**, 219
- Alcohol withdrawal:** Alcohol dependence; NMDA receptor; Excitotoxicity; Primary cortical culture **61**, 155
- Alprazolam:** Caffeine; Drug discrimination; Humans; Novel-response procedure; Triazolam; Zolpidem **61**, 249
- Amantadine:** Cocaine use disorder; Detoxification; Heroin dependence; Methadone; Opioid withdrawal **63**, 187
- Analgesia:** Marijuana smoking; Cannabinoid; Δ^9 -THC; SR 141716A; Antinociception; Catalepsy; Hypothermia **63**, 107
- Analgesia:** κ -Opioids; Locomotor activity; Gender **63**, 215
- Anesthesia:** Naltrexone; ACTH; Cortisol; Craving; Withdrawal **61**, 163
- Antinociception:** Marijuana smoking; Cannabinoid; Δ^9 -THC; SR 141716A; Analgesia; Catalepsy; Hypothermia **63**, 107
- Anti-social personality disorder:** Novelty seeking; Buprenorphine; Heroin dependence; Poly-drug use; Contingency management; Treatment outcome **61**, 287
- Antisocial personality disorder:** Time perception; Cocaine dependence; Contingent negative variation; Evoked potentials; Conduct disorder; EEG **63**, 87
- Antisocial:** Treatment outcome; Substance abuse; Gender; Outpatient **61**, 23
- Assessment:** Cocaine; Follow-up; Treatment **62**, 19
- Attendance:** Outpatient treatment; Substance use diagnosis; Gender; Ethnicity; Employment status **62**, 9
- Australian adults:** DSM-IV; ICD-10; Cannabis dependence **63**, 147
- Automobile driving:** Alcohol; Caffeine; Equilibrium; Psychomotor performance **63**, 123
- Automobile driving licence:** Illegal drugs; Fitness to drive; Drug-Dependence **64**, 19
- Autonomic nervous system:** Immunobiology; Opiates; Nicotinic receptor; Lymphocytes **62**, 141
- Barbiturates:** Benzodiazepine; Pentobarbital; Drug discrimination; Panadiplon (U-78875, PNU-78875); Abuse potential **61**, 229
- Behavioral economics:** Polydrug abuse; Alcohol abuse **62**, 31
- Behavioral incentives:** Pregnancy; Contingency management; Perinatal addictions; Methadone maintenance **61**, 297
- Behavioral treatment:** Smoking cessation; Self-help; Nicotine replacement; Smoking **64**, 35
- Behavior:** Opioid; Morphine; Sex; Gender; Human **63**, 23
- Benzodiazepine:** Abuse potential; CL 284846; Dependence; Feeding; Triazolam; Zaleplon **61**, 69
- Benzodiazepine:** Barbiturates; Pentobarbital; Drug discrimination; Panadiplon (U-78875, PNU-78875); Abuse potential **61**, 229
- Beta-blocker:** Cocaine withdrawal; Propranolol; Pharmacotherapy; Double-blind **63**, 69
- Biochemical mechanisms:** Myopathy; Protein synthesis; Myosin; Acetaldehyde; Metabolism; RNA; Proteolysis; Nutrition; Malnutrition **63**, 199
- Blind dosing:** Methadone maintenance; Drug dependence; Clinic policy; Patient-therapist relationship; Candor; Medical ethics **61**, 191
- Blood:** Methadone; Enantiomer; Addiction; Cytochrome P-450 **61**, 47
- Blood pressure:** Ephedrine; Heart rate; Illicit synthesis; Pseudoephedrine; Rat **64**, 299
- Brain imaging:** Hormonal effects; Magnetic resonance imaging; Cocaine dependence **62**, 49
- Brazil:** Substance misuse; Cocaine; Epidemiological methods; Sampling **63**, 79
- Buprenorphine:** Buprenorphine-naloxone; Dosing regimen; Abuse; Pharmacotherapy **61**, 173

- Buprenorphine**; Heroin dependence; Human; Opioid withdrawal; Treatment 64, 111
- Buprenorphine-naloxone**; Buprenorphine; Dosing regimen; Abuse; Pharmacotherapy 61, 173
- Buprenorphine**; Naloxone; Opiate withdrawal; Sublingual; Pharmacokinetics 61, 85
- Buprenorphine**; Novelty seeking; Anti-social personality disorder; Heroin dependence; Poly-drug use; Contingency management; Treatment outcome 61, 287
- Buprenorphine**; Opiate addiction; Methadone maintenance; Cost-effectiveness 63, 253
- Buprenorphine**; Pain; Methadone; Cold pressor; Hyperalgesia 63, 139
- Buprenorphine**; Pregnancy; Opioid dependence; Treatment; Neonatal abstinence syndrome; Perinatal addiction 63, 97
- Buprenorphine tablet**; Methadone maintenance; Opioids; Controlled trial 62, 97
- Bupropion**; Cocaine; Pharmacotherapy 63, 155
- Caffeine**; Alcohol; Automobile driving; Equilibrium; Psychomotor performance 63, 123
- Caffeine**; Alprazolam; Drug discrimination; Humans; Novel-response procedure; Triazolam; Zolpidem 61, 249
- Candor**; Methadone maintenance; Blind dosing; Drug dependence; Clinic policy; Patient-therapist relationship; Medical ethics 61, 191
- Cannabinoid**; Marijuana smoking; Δ^9 -THC; SR 141716A; Antinociception; Analgesia; Catalepsy; Hypothermia 63, 107
- Cannabis**; Abuse; Cohort; Dependence; Gender; Longitudinal study; Use 64, 347
- Cannabis**; Academic achievement; Adolescence; Coitus; Lack of interest 62, 175
- Cannabis**; Accidents; Respiratory disease; Dependence; Adverse effects 62, 163
- Cannabis**; Comorbidity; Drug use; Population; Alcohol; Tobacco 64, 319
- Cannabis dependence**; DSM-IV; ICD-10; Australian adults 63, 147
- Cannabis**; Substance-related disorders; Epidemiologic studies; Survival analysis; Natural history 64, 123
- Capillarity**; Ethanol; Exercise; Muscle metabolism; Fiber area; Fiber type; Rats 64, 27
- β -carbolines**; Harmine; Harmaline; Hallucinogens; Imidazoline binding sites; SAR 64, 203
- Cardiovascular**; Cocaine; Platelet activation; Methadone; ACE-inhibitors; Fosinopril 61, 35
- Cardiovascular effects**; Cocaine; Pharmacotherapy; Flupentixol; Subjective effects; Pharmacokinetic effects 64, 271
- CART**; Drug abuse; Genes; Gene expression 62, 157
- Case management**; HIV/AIDS; Health service utilization; Drug treatment; Injection drug users 64, 55
- Catalepsy**; Marijuana smoking; Cannabinoid; Δ^9 -THC; SR 141716A; Antinociception; Analgesia; Hypothermia 63, 107
- Catecholamines**; Tyrosine hydroxylase; Cocaine; Mesolimbic pathway; Tropans 61, 15
- Cats**; Lentivirus; Feline immunodeficiency virus (FIV); HIV/AIDS; Immunosuppression; Opiates; Molecular biology 62, 125
- Children**; Injection drug users; HIV; Parental drug use; Children of substance abusing parents; Foster care 61, 113
- Children of substance abusing parents**; Injection drug users; Children; HIV; Parental drug use; Foster care 61, 113
- Choice**; Nitrous oxide; Subjective effects; Reinforcing effects; Abuse liability; Inhalants; Human 64, 85
- CIDI-SAM**; Substance abuse and dependence; Diagnosis; Physiological dependence; Nosology 61, 237
- Cigarette use**; Sensation seeking; Adolescents; Disinhibition; Marijuana use 62, 195
- CL 284846**; Abuse potential; Benzodiazepine; Dependence; Feeding; Triazolam; Zaleplon 61, 69
- CL 284,846**; Abuse potential; Drug discrimination; Feeding; Flumazenil; Pharmacokinetics; Self-administration; Triazolam; Zaleplon; Zolpidem 61, 55
- Clinic policy**; Methadone maintenance; Blind dosing; Drug dependence; Patient-therapist relationship; Candor; Medical ethics 61, 191
- Cluster analysis**; Alcoholic subtype; DSM-IV alcohol dependence; Type I/II-Type A/B 63, 51
- Cocaine**; Assessment; Follow-up; Treatment 62, 19
- Cocaine**; Bupropion; Pharmacotherapy 63, 155
- Cocaine**; Cardiovascular; Platelet activation; Methadone; ACE-inhibitors; Fosinopril 61, 35
- Cocaine**; D2 agonists; Psychomotor stimulant; Self-administration; Positive reinforcement; Rhesus monkey 64, 209
- Cocaine dependence**; Antisocial personality disorder; Time perception; Contingent negative variation; Evoked potentials; Conduct disorder; EEG 63, 87
- Cocaine dependence**; Brain imaging; Hormonal effects; Magnetic resonance imaging 62, 49
- Cocaine dependence**; Cocaine use; Urine test; Treatment outcome 62, 1
- Cocaine dependence**; Pharmacotherapy; Ritanerlin; Serotonin antagonist; Treatment 61, 183

- Cocaine dependence:** Treatment intensity; Psychosocial treatment; Outpatient; Day hospital; Services **61, 145**
- Cocaine:** Depressive symptoms; Depression; Physiological response; Subjective response **63, 131**
- Cocaine:** Fluoxetine; Depression; Dual-diagnosis; Treatment **63, 207**
- Cocaine:** GBR 12909; Phentermine; Progressive ratio; Self-administration; Pharmacotherapy; Abuse potential **62, 41**
- Cocaine:** Longitudinal; Marijuana; Methodology; Survey **62, 239**
- Cocaine:** Methadone; Take-homes; Contingency management; Opiates **62, 69**
- Cocaine:** Methamphetamine; Stimulant; Treatment; HIV **62, 91**
- Cocaine:** Pharmacotherapy; Flupenthixol; Subjective effects; Cardiovascular effects; Pharmacokinetic effects **64, 271**
- Cocaine powder:** Crack; Heroin; Economics; Employment; Gender; Epidemiology **64, 191**
- Cocaine:** Substance misuse; Epidemiological methods; Sampling; Brazil **63, 79**
- Cocaine:** Tyrosine hydroxylase; Catecholamines; Mesolimbic pathway; Tropans **61, 15**
- Cocaine use:** Cocaine dependence; Urine test; Treatment outcome **62, 1**
- Cocaine use disorder:** Amantadine; Detoxification; Heroin dependence; Methadone; Opioid withdrawal **63, 187**
- Cocaine withdrawal:** Prolactin; Cortisol; Serotonin; Dopamine **64, 63**
- Cocaine withdrawal:** Propranolol; Pharmacotherapy; Double-blind; Beta-blocker **63, 69**
- Codeine:** Opioid addiction; Detoxification; Heroin; Methadone **64, 173**
- Cognitions:** Drinking; Gender differences; Response conflict; Gender stereotypes **61, 129**
- Cohort:** Abuse; Cannabis; Dependence; Gender; Longitudinal study; Use **64, 347**
- Coitus:** Academic achievement; Adolescence; Cannabis; Lack of interest **62, 175**
- Cold pressor:** Pain; Methadone; Buprenorphine; Hyperalgesia **63, 139**
- Comorbidity:** Alcoholism; Depressive disorder; Epidemiology **63, 277**
- Comorbidity:** Cannabis; Drug use; Population; Alcohol; Tobacco **64, 319**
- Comorbidity:** Methadone; Treatment outcome; Personality disorders; Psychiatric diagnosis **61, 271**
- Co-morbidity:** Social phobia; Alcohol use; Alcohol challenge; Laboratory stress **64, 219**
- Complications:** Intravenous drug use; Utilization; Services research **64, 117**
- Conduct disorder:** Antisocial personality disorder; Time perception; Cocaine dependence; Contingent negative variation; Evoked potentials; EEG **63, 87**
- Conduct disorder:** Epidemiology; Aggression; Delinquent behavior; Substance-related disorders **63, 245**
- Confirmatory factor analysis:** Alcohol Use Disorders Identification Test (AUDIT); Frequency of drinking; Psychometric analysis; Switzerland **64, 151**
- Contingency management:** Methadone; Take-homes; Opiates; Cocaine **62, 69**
- Contingency management:** Novelty seeking; Anti-social personality disorder; Buprenorphine; Heroin dependence; Poly-drug use; Treatment outcome **61, 287**
- Contingency management:** Pregnancy; Behavioral incentives; Perinatal addictions; Methadone maintenance **61, 297**
- Contingency management:** Substance dependence; Inpatient detoxification; Outpatient aftercare; Treatment compliance **61, 137**
- Contingency management:** Technology transfer; Performance feedback; Incentives; Performance management; Drug treatment counselors **63, 179**
- Contingent negative variation:** Antisocial personality disorder; Time perception; Cocaine dependence; Evoked potentials; Conduct disorder; EEG **63, 87**
- Controlled trial:** Buprenorphine tablet; Methadone maintenance; Opioids **62, 97**
- Convergent analysis:** Hallucinogen Rating Scale (HRS); Immediate versus delayed retrospective assessment; Subjective effects; Reliability **62, 215**
- Correlates:** Gay and Bisexual Men; Young; Substance Use; Prevalence **61, 105**
- Cortisol:** Anesthesia; Naltrexone; ACTH; Craving; Withdrawal **61, 163**
- Cortisol:** Cocaine withdrawal; Prolactin; Serotonin; Dopamine **64, 63**
- Cost-effectiveness:** Opiate addiction; Methadone maintenance; Buprenorphine **63, 253**
- Cost-of-illness:** Heroin; Opiates; Injecting drug use; Methadone; Economics; Policy **61, 195**
- Crack:** Cocaine powder; Heroin; Economics; Employment; Gender; Epidemiology **64, 191**
- Craving:** Anesthesia; Naltrexone; ACTH; Cortisol; Withdrawal **61, 163**
- Craving:** Methamphetamine; Relapse; Treatment **63, 269**

- Cultural factors;** Alcohol dependence; Panic disorder; Major depression; Dysthymia **63**, 117
- Culture;** Adolescence; Alcohol; Dependence; Epidemiology **63**, 229
- Cytochrome P-450;** Methadone; Enantiomer; Blood; Addiction **61**, 47
- D2 agonists;** Psychomotor stimulant; Cocaine; Self-administration; Positive reinforcement; Rhesus monkey **64**, 209
- Dance drugs;** Ecstasy; Dose related neurotoxicity; Polysubstance use; Harm reduction **64**, 9
- Day hospital;** Cocaine dependence; Treatment intensity; Psychosocial treatment; Outpatient; Services **61**, 145
- Death;** Toxicology; Heroin; Morphine; Demographics **61**, 123
- Delinquent behavior;** Epidemiology; Aggression; Conduct disorder; Substance-related disorders **63**, 245
- Demographics;** Toxicology; Heroin; Morphine; Death **61**, 123
- Dependence;** Abuse; Cannabis; Cohort; Gender; Longitudinal study; Use **64**, 347
- Dependence;** Abuse potential; Benzodiazepine; CL 284846; Feeding; Triazolam; Zaleplon **61**, 69
- Dependence;** Adolescence; Alcohol; Culture; Epidemiology **63**, 229
- Dependence;** Cannabis; Accidents; Respiratory disease; Adverse effects **62**, 163
- Dependence;** Heroin; Administration route; SDS scale **63**, 169
- Depression;** Depressive symptoms; Cocaine; Physiological response; Subjective response **63**, 131
- Depression;** Fluoxetine; Cocaine; Dual-diagnosis; Treatment **63**, 207
- Depressive disorder;** Alcoholism; Comorbidity; Epidemiology **63**, 277
- Depressive symptoms;** Depression; Cocaine; Physiological response; Subjective response **63**, 131
- Detoxification;** Amantadine; Cocaine use disorder; Heroin dependence; Methadone; Opioid withdrawal **63**, 187
- Detoxification;** Opioid addiction; Heroin; Methadone; Codeine **64**, 173
- Diagnosis;** Substance abuse and dependence; CIDI-SAM; Physiological dependence; Nosology **61**, 237
- Diagnostic concordance;** Inhalants; Volatile solvents; Nosology **61**, 223
- Discrimination;** Ethanol; Self-administration; Oral **64**, 243
- Disinhibition;** Sensation seeking; Adolescents; Cigarette use; Marijuana use **62**, 195
- Disruptive behaviors;** Adolescents; Alcohol use disorders **64**, 75
- Distressing situations;** Methamphetamine psychosis; Susceptibility; Subsequent flashbacks; Noradrenergic hyperactivity; 3-Methoxytyramine **64**, 133
- Dopamine;** Cocaine withdrawal; Prolactin; Cortisol; Serotonin **64**, 63
- Dopamine receptor responsivity;** Alcohol detoxification; Relapse prediction **64**, 363
- Dose related neurotoxicity;** Ecstasy; Dance drugs; Polysubstance use; Harm reduction **64**, 9
- Dosing regimen;** Buprenorphine; Buprenorphine-naloxone; Abuse; Pharmacotherapy **61**, 173
- Double-blind;** Cocaine withdrawal; Propranolol; Pharmacotherapy; Beta-blocker **63**, 69
- Drinking and driving;** Alcohol abuse; Alcohol consumption; Traffic accidents; Social problems **62**, 231
- Drinking;** Gender differences; Response conflict; Cognitions; Gender stereotypes **61**, 129
- Drinking patterns and costs;** Alcohol use; HMO alcohol costs; U-shaped drinking curve **64**, 181
- Drug abuse;** Adolescent; Sleep problems; Insomnia; Alcohol; Tobacco **64**, 1
- Drug abuse;** Genes; Gene expression; CART **62**, 157
- Drug-Dependence;** Illegal drugs; Automobile driving licence; Fitness to drive **64**, 19
- Drug dependence;** Methadone maintenance; Blind dosing; Clinic policy; Patient-therapist relationship; Candor; Medical ethics **61**, 191
- Drug discrimination;** Abuse potential; CL 284,846; Feeding; Flumazenil; Pharmacokinetics; Self-administration; Triazolam; Zaleplon; Zolpidem **61**, 55
- Drug discrimination;** Alprazolam; Caffeine; Humans; Novel-response procedure; Triazolam; Zolpidem **61**, 249
- Drug discrimination;** Benzodiazepine; Barbiturates; Pentobarbital; Panadiplon (U-78875, PNU-78875); Abuse potential **61**, 229
- Drug discrimination;** Flunitrazepam; Self-administration; Rhesus monkey; Pentobarbital-dependent rats **63**, 39
- Drug-related deaths;** Forensic science; Forensic medicine; Emergency medicine; Drug-related emergencies **61**, 307
- Drug-related emergencies;** Forensic science; Forensic medicine; Emergency medicine; Drug-related deaths **61**, 307
- Drug treatment counselors;** Contingency management; Technology transfer; Performance feedback; Incentives; Performance management **63**, 179
- Drug treatment;** HIV/AIDS; Health service utilization; Case management; Injection drug users **64**, 55
- Drug use;** Cannabis; Comorbidity; Population; Alcohol; Tobacco **64**, 319

- Drug use;** Methadone; Maintenance; Emergency; Mortality **64**, 251
- Drug users;** Age; Sequence of substance use; Opiates; Heroin **64**, 105
- Drug users;** Injection sites; Sydney; Health **62**, 77
- Drug users;** Sexual risk behaviors; Sex partners; HIV **64**, 97
- DSM-IV alcohol dependence;** Alcoholic subtype; Cluster analysis; Type I/II-Type A/B **63**, 51
- DSM-IV;** ICD-10; Cannabis dependence; Australian adults **63**, 147
- Dual-diagnosis;** Fluoxetine; Cocaine; Depression; Treatment **63**, 207
- Dysthymia;** Alcohol dependence; Panic disorder; Cultural factors; Major depression **63**, 117
- Early predictors;** Opiate abuse; Mortality; Vietnam veterans; Follow-up **64**, 309
- Economics;** Crack; Cocaine powder; Heroin; Employment; Gender; Epidemiology **64**, 191
- Economics;** Heroin; Opiates; Injecting drug use; Methadone; Cost-of-illness; Policy **61**, 195
- Ecstasy consumption;** Prevalence; Social class; 18 year-olds **64**, 329
- Ecstasy;** Dance drugs; Dose related neurotoxicity; Polysubstance use; Harm reduction **64**, 9
- EEG;** Antisocial personality disorder; Time perception; Cocaine dependence; Contingent negative variation; Evoked potentials; Conduct disorder **63**, 87
- Emergency;** Drug use; Methadone; Maintenance; Mortality **64**, 251
- Emergency medicine;** Forensic science; Forensic medicine; Drug-related emergencies; Drug-related deaths **61**, 307
- Emotional support;** Methadone patients; Social relationships; Needle sharing; Intravenous drug use **64**, 47
- Employment;** Crack; Cocaine powder; Heroin; Economics; Gender; Epidemiology **64**, 191
- Employment status;** Outpatient treatment; Substance use diagnosis; Gender; Ethnicity; Attendance **62**, 9
- Enantiomer;** Methadone; Blood; Addiction; Cytochrome P-450 **61**, 47
- Ephedrine;** Blood pressure; Heart rate; Illicit synthesis; Pseudoephedrine; Rat **64**, 299
- Epidemiological methods;** Substance misuse; Cocaine; Sampling; Brazil **63**, 79
- Epidemiological survey;** Substance abuse; Opiate users; Maintenance treatments; Harm reduction policies **61**, 281
- Epidemiologic studies;** Substance-related disorders; Cannabis; Survival analysis; Natural history **64**, 123
- Epidemiology;** Adolescence; Alcohol; Culture; Dependence **63**, 229
- Epidemiology;** Aggression; Delinquent behavior; Conduct disorder; Substance-related disorders **63**, 245
- Epidemiology;** Alcoholism; Depressive disorder; Comorbidity **63**, 277
- Epidemiology;** Crack; Cocaine powder; Heroin; Economics; Employment; Gender **64**, 191
- Epidemiology;** *Gamma*-hydroxybutyrate; GHB, abuse potential, pharmacology; Patterns of use and abuse; Review **63**, 1
- Epidemiology;** HIV; Injection drug users; Risk reduction; Time-trends **61**, 315
- Equilibrium;** Alcohol; Caffeine; Automobile driving; Psychomotor performance **63**, 123
- Ethanol;** Discrimination; Self-administration; Oral **64**, 243
- Ethanol;** Exercise; Muscle metabolism; Fiber area; Fiber type; Capillarity; Rats **64**, 27
- Ethanol;** Plasma Δ^9 -tetrahydrocannabinol (THC) levels; Polydrug abuse; Marijuana; Human subjects **64**, 143
- Ethnicity;** Outpatient treatment; Substance use diagnosis; Gender; Employment status; Attendance **62**, 9
- Evoked potentials;** Antisocial personality disorder; Time perception; Cocaine dependence; Contingent negative variation; Conduct disorder; EEG **63**, 87
- Excitotoxicity;** Alcohol dependence; Alcohol withdrawal; NMDA receptor; Primary cortical culture **61**, 155
- Exercise;** Ethanol; Muscle metabolism; Fiber area; Fiber type; Capillarity; Rats **64**, 27
- Family history;** Heroin addiction; Genetics; Treatment outcome; Methadone; Maintenance **61**, 261
- Feeding;** Abuse potential; Benzodiazepine; CL 284846; Dependence; Triazolam; Zaleplon **61**, 69
- Feeding;** Abuse potential; CL 284,846; Drug discrimination; Flumazenil; Pharmacokinetics; Self-administration; Triazolam; Zaleplon; Zolpidem **61**, 55
- Feline immunodeficiency virus (FIV);** Lentivirus; HIV/AIDS; Immunosuppression; Opiates; Molecular biology; Cats **62**, 125
- Fenfluramine;** Alcohol; Prolactin; SSRI **63**, 263
- Fiber area;** Ethanol; Exercise; Muscle metabolism; Fiber type; Capillarity; Rats **64**, 27
- Fiber type;** Ethanol; Exercise; Muscle metabolism; Fiber area; Capillarity; Rats **64**, 27
- Fitness to drive;** Illegal drugs; Automobile driving licence; Drug-Dependence **64**, 19
- Flumazenil;** Abuse potential; CL 284,846; Drug discrimination; Feeding; Pharmacokinetics; Self-administration; Triazolam; Zaleplon; Zolpidem **61**, 55

- Flunitrazepam:** Absorption rate; Pharmacokinetics; Rate of onset of effects; Abuse liability **64**, 285
- Flunitrazepam:** Drug discrimination; Self-administration; Rhesus monkey; Pentobarbital-dependent rats **63**, 39
- Fluoxetine:** Cocaine; Depression; Dual-diagnosis; Treatment **63**, 207
- Flupenthixol:** Cocaine; Pharmacotherapy; Subjective effects; Cardiovascular effects; Pharmacokinetic effects **64**, 271
- Follow-up:** Cocaine; Assessment; Treatment **62**, 19
- Follow-up:** Opiate abuse; Mortality; Early predictors; Vietnam veterans **64**, 309
- Forensic medicine:** Forensic science; Emergency medicine; Drug-related emergencies; Drug-related deaths **61**, 307
- Forensic science:** Forensic medicine; Emergency medicine; Drug-related emergencies; Drug-related deaths **61**, 307
- Fosinopril:** Cocaine; Cardiovascular; Platelet activation; Methadone; ACE-inhibitors **61**, 35
- Foster care:** Injection drug users; Children; HIV; Parental drug use; Children of substance abusing parents **61**, 113
- Frequency of drinking:** Alcohol Use Disorders Identification Test (AUDIT); Psychometric analysis; Switzerland; Confirmatory factor analysis **64**, 151
- Gambling:** Substance abuse; Impulsivity **63**, 29
- Gamma-amino-butyric acid:** Alcoholism; Gamma-hydroxy-butyric acid; Growth hormone **61**, 217
- Gamma-hydroxybutyrate:** GHB, abuse potential, pharmacology; Patterns of use and abuse; Epidemiology; Review **63**, 1
- Gamma-hydroxy-butyric acid:** Alcoholism; Gamma-amino-butyric acid; Growth hormone **61**, 217
- Gay and Bisexual Men:** Young; Substance Use; Prevalence; Correlates **61**, 105
- GBR 12909:** Cocaine; Phentermine; Progressive ratio; Self-administration; Pharmacotherapy; Abuse potential **62**, 41
- Gender:** Abuse; Cannabis; Cohort; Dependence; Longitudinal study; Use **64**, 347
- Gender:** Antisocial; Treatment outcome; Substance abuse; Outpatient **61**, 23
- Gender:** Crack; Cocaine powder; Heroin; Economics; Employment; Epidemiology **64**, 191
- Gender differences:** Drinking; Response conflict; Cognitions; Gender stereotypes **61**, 129
- Gender:** Opioid; Morphine; Sex; Behavior; Human **63**, 23
- Gender:** κ -Opioids; Analgesia; Locomotor activity **63**, 215
- Gender:** Outpatient treatment; Substance use diagnosis; Ethnicity; Employment status; Attendance **62**, 9
- Gender stereotypes:** Drinking; Gender differences; Response conflict; Cognitions **61**, 129
- Gene expression:** Drug abuse; Genes; CART **62**, 157
- Gene induction:** Mu-receptor; T-lymphocyte; Morphine; Mitogen **62**, 131
- Genes:** Drug abuse; Gene expression; CART **62**, 157
- Genetic:** Alcohol dependence; Illicit drug dependence; Posttraumatic stress disorder; Twins; Veterans **61**, 95
- Genetic and environmental influences:** Marijuana use; Sensation seeking; Risk taking; Add health study **62**, 57
- Genetics:** Heroin addiction; Family history; Treatment outcome; Methadone; Maintenance **61**, 261
- GHB, abuse potential, pharmacology:** Gamma-hydroxybutyrate; Patterns of use and abuse; Epidemiology; Review **63**, 1
- Growth hormone:** Alcoholism; Gamma-amino-butyric acid; Gamma-hydroxy-butyric acid **61**, 217
- Hallucinogen Rating Scale (HRS):** Immediate versus delayed retrospective assessment; Subjective effects; Reliability; Convergent analysis **62**, 215
- Hallucinogens:** β -carbolines; Harmine; Harmaline; Imidazoline binding sites; SAR **64**, 203
- Harmaline:** β -carbolines; Harmine; Hallucinogens; Imidazoline binding sites; SAR **64**, 203
- Harmine:** β -carbolines; Harmaline; Hallucinogens; Imidazoline binding sites; SAR **64**, 203
- Harm reduction:** Ecstasy; Dance drugs; Dose related neurotoxicity; Polysubstance use **64**, 9
- Harm reduction policies:** Substance abuse; Opiate users; Maintenance treatments; Epidemiological survey **61**, 281
- Health:** Injection sites; Drug users; Sydney **62**, 77
- Health service utilization:** HIV/AIDS; Case management; Drug treatment; Injection drug users **64**, 55
- Heart rate:** Blood pressure; Ephedrine; Illicit synthesis; Pseudoephedrine; Rat **64**, 299
- Heavy drinkers:** Alcohol; Negative reinforcement **64**, 337
- Helplines:** Substance-related disorders; Therapy **62**, 191
- Hepatitis B:** Hepatitis C; Methadone; Injection drug users; Sexually transmitted disease **61**, 211
- Hepatitis C:** Hepatitis B; Methadone; Injection drug users; Sexually transmitted disease **61**, 211
- Heroin addiction:** Family history; Genetics; Treatment outcome; Methadone; Maintenance **61**, 261

- Heroin**; Age; Sequence of substance use; Drug users; Opiates 64, 105
- Heroin**; Crack; Cocaine powder; Economics; Employment; Gender; Epidemiology 64, 191
- Heroin**; Dependence; Administration route; SDS scale 63, 169
- Heroin dependence**; Amantadine; Cocaine use disorder; Detoxification; Methadone; Opioid withdrawal 63, 187
- Heroin dependence**; Buprenorphine; Human; Opioid withdrawal; Treatment 64, 111
- Heroin dependence**; Novelty seeking; Anti-social personality disorder; Buprenorphine; Poly-drug use; Contingency management; Treatment outcome 61, 287
- Heroin**; Opiates; Injecting drug use; Methadone; Cost-of-illness; Economics; Policy 61, 195
- Heroin**; Opioid addiction; Detoxification; Methadone; Codeine 64, 173
- Heroin**; Toxicology; Morphine; Death; Demographics 61, 123
- HIV/AIDS**; Health service utilization; Case management; Drug treatment; Injection drug users 64, 55
- HIV/AIDS**; Lentivirus; Feline immunodeficiency virus (FIV); Immunosuppression; Opiates; Molecular biology; Cats 62, 125
- HIV/AIDS**; U50,488; κ -Opioid receptors; Immunobiology; Macrophages; RANTES 62, 149
- HIV**; Drug users; Sexual risk behaviors; Sex partners 64, 97
- HIV**; Injection drug users; Children; Parental drug use; Children of substance abusing parents; Foster care 61, 113
- HIV**; Injection drug users; Risk reduction; Epidemiology; Time-trends 61, 315
- HIV**; Methamphetamine; Cocaine; Stimulant; Treatment 62, 91
- HIV prevention**; Injection drug use; Substance abuse; Syringe exchange programs; Treatment 62, 225
- HIV review**; Opiate abuse; Immune function; Immunobiology; Molecular biology 62, 111
- HMO alcohol costs**; Alcohol use; Drinking patterns and costs; U-shaped drinking curve 64, 181
- Hormonal effects**; Brain imaging; Magnetic resonance imaging; Cocaine dependence 62, 49
- Human**; Buprenorphine; Heroin dependence; Opioid withdrawal; Treatment 64, 111
- Human immunodeficiency virus**; Indinavir; Naloxone; Naltrexone; Zidovudine 64, 257
- Human**; Nitrous oxide; Subjective effects; Choice; Reinforcing effects; Abuse liability; Inhalants 64, 85
- Human**; Opioid; Morphine; Sex; Gender; Behavior 63, 23
- Humans**; Alprazolam; Caffeine; Drug discrimination; Novel-response procedure; Triazolam; Zolpidem 61, 249
- Human subjects**; Ethanol; Plasma Δ^9 -tetrahydrocannabinol (THC) levels; Polydrug abuse; Marihuana 64, 143
- Hyperalgesia**; Pain; Methadone; Buprenorphine; Cold pressor 63, 139
- Hypothermia**; Marijuana smoking; Cannabinoid; Δ^9 -THC; SR 141716A; Antinociception; Analgesia; Catalepsy 63, 107
- ICD-10**; DSM-IV; Cannabis dependence; Australian adults 63, 147
- Illegal drugs**; Automobile driving licence; Fitness to drive; Drug-Dependence 64, 19
- Illicit drug dependence**; Alcohol dependence; Genetic; Posttraumatic stress disorder; Twins; Veterans 61, 95
- Illicit drugs**; Medical students; Pre-registration house officers; Alcohol; Stress 64, 265
- Illicit synthesis**; Blood pressure; Ephedrine; Heart rate; Pseudoephedrine; Rat 64, 299
- Imidazoline binding sites**; β -carbolines; Harmine; Harmaline; Hallucinogens; SAR 64, 203
- Immediate versus delayed retrospective assessment**; Hallucinogen Rating Scale (HRS); Subjective effects; Reliability; Convergent analysis 62, 215
- Immune function**; Opiate abuse; Immunobiology; Molecular biology; HIV review 62, 111
- Immunobiology**; HIV/AIDS; U50,488; κ -Opioid receptors; Macrophages; RANTES 62, 149
- Immunobiology**; Opiate abuse; Immune function; Molecular biology; HIV review 62, 111
- Immunobiology**; Opiates; Nicotinic receptor; Lymphocytes; Autonomic nervous system 62, 141
- Immunosuppression**; Lentivirus; Feline immunodeficiency virus (FIV); HIV/AIDS; Opiates; Molecular biology; Cats 62, 125
- Impulsivity**; Substance abuse; Gambling 63, 29
- Incentives**; Contingency management; Technology transfer; Performance feedback; Performance management; Drug treatment counselors 63, 179
- Indinavir**; Human immunodeficiency virus; Naloxone; Naltrexone; Zidovudine 64, 257
- Inhalants**; Nitrous oxide; Subjective effects; Choice; Reinforcing effects; Abuse liability; Human 64, 85
- Inhalants**; Volatile solvents; Nosology; Diagnostic concordance 61, 223
- Injecting drug use**; Heroin; Opiates; Methadone; Cost-of-illness; Economics; Policy 61, 195

- Injection drug users;** Children; HIV; Parental drug use; Children of substance abusing parents; Foster care 61, 113
- Injection drug users;** Hepatitis C; Hepatitis B; Methadone; Sexually transmitted disease 61, 211
- Injection drug users;** HIV/AIDS; Health service utilization; Case management; Drug treatment 64, 55
- Injection drug users;** HIV; Risk reduction; Epidemiology; Time-trends 61, 315
- Injection drug use;** Stimulants; Substance abuse treatment; Psychological symptoms 64, 165
- Injection drug use;** Substance abuse; Syringe exchange programs; HIV prevention; Treatment 62, 225
- Injection sites;** Drug users; Sydney; Health 62, 77
- Inpatient detoxification;** Substance dependence; Contingency management; Outpatient aftercare; Treatment compliance 61, 137
- Insomnia;** Adolescent; Sleep problems; Alcohol; Tobacco; Drug abuse 64, 1
- Intravenous drug use;** Methadone patients; Social relationships; Needle sharing; Emotional support 64, 47
- Intravenous drug use;** Utilization; Complications; Services research 64, 117
- Laboratory stress;** Social phobia; Co-morbidity; Alcohol use; Alcohol challenge 64, 219
- Lack of interest;** Academic achievement; Adolescence; Cannabis; Coitus 62, 175
- Lentivirus;** Feline immunodeficiency virus (FIV); HIV/AIDS; Immunosuppression; Opiates; Molecular biology; Cats 62, 125
- Liability;** Puberty; Adolescence; Affective, cognitive, and behavioral dysregulation; Neuroadaptation; Substance use disorder 61, 3
- Locomotor activity;** Morphine; Sensitization; Rats 62, 83
- Locomotor activity;** κ -Opioids; Analgesia; Gender 63, 215
- Longitudinal;** Cocaine; Marijuana; Methodology; Survey 62, 239
- Longitudinal study;** Abuse; Cannabis; Cohort; Dependence; Gender; Use 64, 347
- Lymphocytes;** Immunobiology; Opiates; Nicotinic receptor; Autonomic nervous system 62, 141
- Macrophages;** HIV/AIDS; U50,488; κ -Opioid receptors; Immunobiology; RANTES 62, 149
- Magnetic resonance imaging;** Brain imaging; Hormonal effects; Cocaine dependence 62, 49
- Maintenance;** Drug use; Methadone; Emergency; Mortality 64, 251
- Maintenance;** Heroin addiction; Family history; Genetics; Treatment outcome; Methadone 61, 261
- Maintenance treatments;** Substance abuse; Opiate users; Epidemiological survey; Harm reduction policies 61, 281
- Major depression;** Alcohol dependence; Panic disorder; Cultural factors; Dysthymia 63, 117
- Malnutrition;** Myopathy; Biochemical mechanisms; Protein synthesis; Myosin; Acetaldehyde; Metabolism; RNA; Proteolysis; Nutrition 63, 199
- Marihuana;** Ethanol; Plasma Δ^9 -tetrahydrocannabinol (THC) levels; Polydrug abuse; Human subjects 64, 143
- Marijuana;** Cocaine; Longitudinal; Methodology; Survey 62, 239
- Marijuana smoking;** Cannabinoid; Δ^9 -THC; SR 141716A; Antinociception; Analgesia; Catalepsy; Hypothermia 63, 107
- Marijuana use;** Genetic and environmental influences; Sensation seeking; Risk taking; Add health study 62, 57
- Marijuana use;** Sensation seeking; Adolescents; Cigarette use; Disinhibition 62, 195
- Medical ethics;** Methadone maintenance; Blind dosing; Drug dependence; Clinic policy; Patient-therapist relationship; Candor 61, 191
- Medical students;** Pre-registration house officers; Alcohol; Illicit drugs; Stress 64, 265
- Mesolimbic pathway;** Tyrosine hydroxylase; Catecholamines; Cocaine; Tropans 61, 15
- Metabolism;** Myopathy; Biochemical mechanisms; Protein synthesis; Myosin; Acetaldehyde; RNA; Proteolysis; Nutrition; Malnutrition 63, 199
- Methadone;** Amantadine; Cocaine use disorder; Detoxification; Heroin dependence; Opioid withdrawal 63, 187
- Methadone;** Cocaine; Cardiovascular; Platelet activation; ACE-inhibitors; Fosinopril 61, 35
- Methadone;** Drug use; Maintenance; Emergency; Mortality 64, 251
- Methadone;** Enantiomer; Blood; Addiction; Cytochrome P-450 61, 47
- Methadone;** Hepatitis C; Hepatitis B; Injection drug users; Sexually transmitted disease 61, 211
- Methadone;** Heroin addiction; Family history; Genetics; Treatment outcome; Maintenance 61, 261
- Methadone;** Heroin; Opiates; Injecting drug use; Cost-of-illness; Economics; Policy 61, 195
- Methadone maintenance;** Blind dosing; Drug dependence; Clinic policy; Patient-therapist relationship; Candor; Medical ethics 61, 191
- Methadone maintenance;** Buprenorphine tablet; Opioids; Controlled trial 62, 97
- Methadone maintenance;** Opiate addiction; Buprenorphine; Cost-effectiveness 63, 253

- Methadone maintenance:** Pregnancy; Behavioral incentives; Contingency management; Perinatal addictions **61**, 297
- Methadone maintenance treatment:** Methadone reduction treatment **62**, 255
- Methadone:** Opioid addiction; Detoxification; Heroin; Codeine **64**, 173
- Methadone:** Pain; Buprenorphine; Cold pressor; Hyperalgesia **63**, 139
- Methadone patients:** Social relationships; Needle sharing; Intravenous drug use; Emotional support **64**, 47
- Methadone reduction treatment:** Methadone maintenance treatment **62**, 255
- Methadone:** Take-homes; Contingency management; Opiates; Cocaine **62**, 69
- Methadone:** Treatment outcome; Personality disorders; Psychiatric diagnosis; Comorbidity **61**, 271
- Methamphetamine:** Cocaine; Stimulant; Treatment; HIV **62**, 91
- Methamphetamine:** Craving; Relapse; Treatment **63**, 269
- Methamphetamine psychosis:** Susceptibility; Subsequent flashbacks; Noradrenergic hyperactivity; 3-Methoxytyramine; Distressing situations **64**, 133
- Methodology:** Cocaine; Longitudinal; Marijuana; Survey **62**, 239
- 3-Methoxytyramine:** Methamphetamine psychosis; Susceptibility; Subsequent flashbacks; Noradrenergic hyperactivity; Distressing situations **64**, 133
- Mitogen:** Mu-receptor; T-lymphocyte; Morphine; Gene induction **62**, 131
- Molecular biology:** Lentivirus; Feline immunodeficiency virus (FIV); HIV/AIDS; Immunosuppression; Opiates; Cats **62**, 125
- Molecular biology:** Opiate abuse; Immune function; Immunobiology; HIV review **62**, 111
- Morphine:** Mu-receptor; T-lymphocyte; Mitogen; Gene induction **62**, 131
- Morphine:** Opioid; Sex; Gender; Behavior; Human **63**, 23
- Morphine:** Sensitization; Locomotor activity; Rats **62**, 83
- Morphine:** Toxicology; Heroin; Death; Demographics **61**, 123
- Mortality:** Drug use; Methadone; Maintenance; Emergency **64**, 251
- Mortality:** Opiate abuse; Early predictors; Vietnam veterans; Follow-up **64**, 309
- Mu-receptor:** T-lymphocyte; Morphine; Mitogen; Gene induction **62**, 131
- Muscle metabolism:** Ethanol; Exercise; Fiber area; Fiber type; Capillarity; Rats **64**, 27
- Myopathy:** Biochemical mechanisms; Protein synthesis; Myosin; Acetaldehyde; Metabolism; RNA; Proteolysis; Nutrition; Malnutrition **63**, 199
- Myosin:** Myopathy; Biochemical mechanisms; Protein synthesis; Acetaldehyde; Metabolism; RNA; Proteolysis; Nutrition; Malnutrition **63**, 199
- Naloxone:** Buprenorphine; Opiate withdrawal; Sublingual; Pharmacokinetics **61**, 85
- Naloxone:** Human immunodeficiency virus; Indinavir; Naltrexone; Zidovudine **64**, 257
- Naltrexone:** Anesthesia; ACTH; Cortisol; Craving; Withdrawal **61**, 163
- Naltrexone:** Human immunodeficiency virus; Indinavir; Naloxone; Zidovudine **64**, 257
- Natural history:** Substance-related disorders; Cannabis; Epidemiologic studies; Survival analysis **64**, 123
- Needle sharing:** Methadone patients; Social relationships; Intravenous drug use; Emotional support **64**, 47
- Negative reinforcement:** Alcohol; Heavy drinkers **64**, 337
- Neonatal abstinence syndrome:** Pregnancy; Buprenorphine; Opioid dependence; Treatment; Perinatal addiction **63**, 97
- Neuroadaptation:** Liability; Puberty; Adolescence; Affective, cognitive, and behavioral dysregulation; Substance use disorder **61**, 3
- Nicotine replacement:** Smoking cessation; Self-help; Behavioral treatment; Smoking **64**, 35
- Nicotinic receptor:** Immunobiology; Opiates; Lymphocytes; Autonomic nervous system **62**, 141
- Nitrous oxide:** Subjective effects; Choice; Reinforcing effects; Abuse liability; Inhalants; Human **64**, 85
- NMDA receptor:** Alcohol dependence; Alcohol withdrawal; Excitotoxicity; Primary cortical culture **61**, 155
- Noradrenergic hyperactivity:** Methamphetamine psychosis; Susceptibility; Subsequent flashbacks; 3-Methoxytyramine; Distressing situations **64**, 133
- Nosology:** Inhalants; Volatile solvents; Diagnostic concordance **61**, 223
- Nosology:** Substance abuse and dependence; Diagnosis; CIDI-SAM; Physiological dependence **61**, 237
- Novel-response procedure:** Alprazolam; Caffeine; Drug discrimination; Humans; Triazolam; Zolpidem **61**, 249
- Novelty seeking:** Anti-social personality disorder; Buprenorphine; Heroin dependence; Poly-drug use; Contingency management; Treatment outcome **61**, 287
- Nutrition:** Myopathy; Biochemical mechanisms; Protein synthesis; Myosin; Acetaldehyde; Metabolism; RNA; Proteolysis; Malnutrition **63**, 199

- Opiate abuse:** Immune function; Immunobiology; Molecular biology; HIV review **62**, 111
- Opiate abuse:** Mortality; Early predictors; Vietnam veterans; Follow-up **64**, 309
- Opiate addiction:** Methadone maintenance; Buprenorphine; Cost-effectiveness **63**, 253
- Opiates:** Age; Sequence of substance use; Drug users; Heroin **64**, 105
- Opiates:** Heroin; Injecting drug use; Methadone; Cost-of-illness; Economics; Policy **61**, 195
- Opiates:** Immunobiology; Nicotinic receptor; Lymphocytes; Autonomic nervous system **62**, 141
- Opiates:** Lentivirus; Feline immunodeficiency virus (FIV); HIV/AIDS; Immunosuppression; Molecular biology; Cats **62**, 125
- Opiates:** Methadone; Take-homes; Contingency management; Cocaine **62**, 69
- Opiate users:** Substance abuse; Maintenance treatments; Epidemiological survey; Harm reduction policies **61**, 281
- Opiate withdrawal:** Buprenorphine; Naloxone; Sublingual; Pharmacokinetics **61**, 85
- Opioid addiction:** Detoxification; Heroin; Methadone; Codeine **64**, 173
- Opioid dependence:** Pregnancy; Buprenorphine; Treatment; Neonatal abstinence syndrome; Perinatal addiction **63**, 97
- Opioid:** Morphine; Sex; Gender; Behavior; Human **63**, 23
- κ -Opioid receptors:** HIV/AIDS; U50,488; Immunobiology; Macrophages; RANTES **62**, 149
- κ -Opioids:** Analgesia; Locomotor activity; Gender **63**, 215
- Opioids:** Buprenorphine tablet; Methadone maintenance; Controlled trial **62**, 97
- Opioids:** Tolerance; Rhesus monkeys; Self-administration **62**, 181
- Opioid withdrawal:** Amantadine; Cocaine use disorder; Detoxification; Heroin dependence; Methadone **63**, 187
- Opioid withdrawal:** Buprenorphine; Heroin dependence; Human; Treatment **64**, 111
- Oral:** Ethanol; Discrimination; Self-administration **64**, 243
- Outpatient aftercare:** Substance dependence; Contingency management; Inpatient detoxification; Treatment compliance **61**, 137
- Outpatient:** Antisocial; Treatment outcome; Substance abuse; Gender **61**, 23
- Outpatient:** Cocaine dependence; Treatment intensity; Psychosocial treatment; Day hospital; Services **61**, 145
- Outpatient treatment:** Substance use diagnosis; Gender; Ethnicity; Employment status; Attendance **62**, 9
- Pain:** Methadone; Buprenorphine; Cold pressor; Hyperalgesia **63**, 139
- Panadiplon (U-78875, PNU-78875):** Benzodiazepine; Barbiturates; Pentobarbital; Drug discrimination; Abuse potential **61**, 229
- Panic disorder:** Alcohol dependence; Cultural factors; Major depression; Dysthymia **63**, 117
- Parental drug use:** Injection drug users; Children; HIV; Children of substance abusing parents; Foster care **61**, 113
- Patient-therapist relationship:** Methadone maintenance; Blind dosing; Drug dependence; Clinic policy; Candor; Medical ethics **61**, 191
- Patterns of use and abuse:** *Gamma*-hydroxybutyrate; GHB, abuse potential, pharmacology; Epidemiology; Review **63**, 1
- Pentobarbital:** Benzodiazepine; Barbiturates; Drug discrimination; Panadiplon (U-78875, PNU-78875); Abuse potential **61**, 229
- Pentobarbital-dependent rats:** Flunitrazepam; Drug discrimination; Self-administration; Rhesus monkey **63**, 39
- Performance feedback:** Contingency management; Technology transfer; Incentives; Performance management; Drug treatment counselors **63**, 179
- Performance management:** Contingency management; Technology transfer; Performance feedback; Incentives; Drug treatment counselors **63**, 179
- Perinatal addiction:** Pregnancy; Buprenorphine; Opioid dependence; Treatment; Neonatal abstinence syndrome **63**, 97
- Perinatal addictions:** Pregnancy; Behavioral incentives; Contingency management; Methadone maintenance **61**, 297
- Personality disorders:** Methadone; Treatment outcome; Psychiatric diagnosis; Comorbidity **61**, 271
- Pharmacokinetic effects:** Cocaine; Pharmacotherapy; Flupenthixol; Subjective effects; Cardiovascular effects **64**, 271
- Pharmacokinetics:** Abuse potential; CL 284,846; Drug discrimination; Feeding; Flumazenil; Self-administration; Triazolam; Zaleplon; Zolpidem **61**, 55
- Pharmacokinetics:** Buprenorphine; Naloxone; Opiate withdrawal; Sublingual **61**, 85
- Pharmacokinetics:** Flunitrazepam; Absorption rate; Rate of onset of effects; Abuse liability **64**, 285
- Pharmacotherapy:** Buprenorphine; Buprenorphine-naloxone; Dosing regimen; Abuse **61**, 173
- Pharmacotherapy:** Cocaine; Bupropion **63**, 155
- Pharmacotherapy:** Cocaine; Flupenthixol; Subjective effects; Cardiovascular effects; Pharmacokinetic effects **64**, 271
- Pharmacotherapy:** Cocaine; GBR 12909; Phentermine; Progressive ratio; Self-administration; Abuse potential **62**, 41
- Pharmacotherapy:** Cocaine withdrawal; Propranolol; Double-blind; Beta-blocker **63**, 69

- Pharmacotherapy:** Ritanerlin; Cocaine dependence; Serotonin antagonist; Treatment 61, 183
- Phentermine:** Cocaine; GBR 12909; Progressive ratio; Self-administration; Pharmacotherapy; Abuse potential 62, 41
- Physiological dependence:** Substance abuse and dependence; Diagnosis; CIDI-SAM; Nosology 61, 237
- Physiological response:** Depressive symptoms; Depression; Cocaine; Subjective response 63, 131
- Plasma Δ^9 -tetrahydrocannabinol (THC) levels:** Ethanol; Polydrug abuse; Marihuana; Human subjects 64, 143
- Platelet activation:** Cocaine; Cardiovascular; Methadone; ACE-inhibitors; Fosinopril 61, 35
- Policy:** Heroin; Opiates; Injecting drug use; Methadone; Cost-of-illness; Economics 61, 195
- Polydrug abuse:** Alcohol abuse; Behavioral economics 62, 31
- Polydrug abuse:** Ethanol; Plasma Δ^9 -tetrahydrocannabinol (THC) levels; Marihuana; Human subjects 64, 143
- Poly-drug use:** Novelty seeking; Anti-social personality disorder; Buprenorphine; Heroin dependence; Contingency management; Treatment outcome 61, 287
- Polysubstance use:** Ecstasy; Dance drugs; Dose related neurotoxicity; Harm reduction 64, 9
- Population:** Cannabis; Comorbidity; Drug use; Alcohol; Tobacco 64, 319
- Positive reinforcement:** D2 agonists; Psychomotor stimulant; Cocaine; Self-administration; Rhesus monkey 64, 209
- Posttraumatic stress disorder:** Alcohol dependence; Genetic; Illicit drug dependence; Twins; Veterans 61, 95
- Pregnancy:** Behavioral incentives; Contingency management; Perinatal addictions; Methadone maintenance 61, 297
- Pregnancy:** Buprenorphine; Opioid dependence; Treatment; Neonatal abstinence syndrome; Perinatal addiction 63, 97
- Pre-registration house officers:** Medical students; Alcohol; Illicit drugs; Stress 64, 265
- Prevalence:** Ecstasy consumption; Social class; 18 year-olds 64, 329
- Prevalence:** Gay and Bisexual Men; Young; Substance Use; Correlates 61, 105
- Primary cortical culture:** Alcohol dependence; Alcohol withdrawal; NMDA receptor; Excitotoxicity 61, 155
- Progressive ratio:** Cocaine; GBR 12909; Phentermine; Self-administration; Pharmacotherapy; Abuse potential 62, 41
- Prolactin:** Alcohol; Fenfluramine; SSRI 63, 263
- Prolactin:** Cocaine withdrawal; Cortisol; Serotonin; Dopamine 64, 63
- Propranolol:** Cocaine withdrawal; Pharmacotherapy; Double-blind; Beta-blocker 63, 69
- Protein synthesis:** Myopathy; Biochemical mechanisms; Myosin; Acetaldehyde; Metabolism; RNA; Proteolysis; Nutrition; Malnutrition 63, 199
- Proteolysis:** Myopathy; Biochemical mechanisms; Protein synthesis; Myosin; Acetaldehyde; Metabolism; RNA; Nutrition; Malnutrition 63, 199
- Pseudoephedrine:** Blood pressure; Ephedrine; Heart rate; Illicit synthesis; Rat 64, 299
- Psychiatric diagnosis:** Methadone; Treatment outcome; Personality disorders; Comorbidity 61, 271
- Psychological symptoms:** Injection drug use; Stimulants; Substance abuse treatment 64, 165
- Psychometric analysis:** Alcohol Use Disorders Identification Test (AUDIT); Frequency of drinking; Switzerland; Confirmatory factor analysis 64, 151
- Psychomotor performance:** Alcohol; Caffeine; Automobile driving; Equilibrium 63, 123
- Psychomotor stimulant:** D2 agonists; Cocaine; Self-administration; Positive reinforcement; Rhesus monkey 64, 209
- Psychosocial treatment:** Cocaine dependence; Treatment intensity; Outpatient; Day hospital; Services 61, 145
- Puberty:** Liability; Adolescence; Affective, cognitive, and behavioral dysregulation; Neuroadaptation; Substance use disorder 61, 3
- RANTES:** HIV/AIDS; U50,488; κ -Opioid receptors; Immunobiology; Macrophages 62, 149
- Rat:** Blood pressure; Ephedrine; Heart rate; Illicit synthesis; Pseudoephedrine 64, 299
- Rate of onset of effects:** Flunitrazepam; Absorption rate; Pharmacokinetics; Abuse liability 64, 285
- Rats:** Ethanol; Exercise; Muscle metabolism; Fiber area; Fiber type; Capillarity 64, 27
- Rats:** Morphine; Sensitization; Locomotor activity 62, 83
- Reinforcing effects:** Nitrous oxide; Subjective effects; Choice; Abuse liability; Inhalants; Human 64, 85
- Relapse:** Craving; Methamphetamine; Treatment 63, 269
- Relapse prediction:** Dopamine receptor responsivity; Alcohol detoxification 64, 363
- Reliability:** Hallucinogen Rating Scale (HRS); Immediate versus delayed retrospective assessment; Subjective effects; Convergent analysis 62, 215
- Respiratory disease:** Cannabis; Accidents; Dependence; Adverse effects 62, 163
- Response conflict:** Drinking; Gender differences; Cognitions; Gender stereotypes 61, 129

- Review;** *Gamma*-hydroxybutyrate; GHB, abuse potential, pharmacology; Patterns of use and abuse; Epidemiology 63, 1
- Rhesus monkey;** D2 agonists; Psychomotor stimulant; Cocaine; Self-administration; Positive reinforcement 64, 209
- Rhesus monkey;** Flunitrazepam; Drug discrimination; Self-administration; Pentobarbital-dependent rats 63, 39
- Rhesus monkeys;** Tolerance; Opioids; Self-administration 62, 181
- Risk reduction;** HIV; Injection drug users; Epidemiology; Time-trends 61, 315
- Risk taking;** Genetic and environmental influences; Marijuana use; Sensation seeking; Add health study 62, 57
- Ritanserin;** Pharmacotherapy; Cocaine dependence; Serotonin antagonist; Treatment 61, 183
- RNA;** Myopathy; Biochemical mechanisms; Protein synthesis; Myosin; Acetaldehyde; Metabolism; Proteolysis; Nutrition; Malnutrition 63, 199
- Sampling;** Substance misuse; Cocaine; Epidemiological methods; Brazil 63, 79
- SAR;** β -carbolines; Harmine; Harmaline; Hallucinogens; Imidazoline binding sites 64, 203
- SDS scale;** Heroin; Dependence; Administration route 63, 169
- Self-administration;** Abuse potential; CL 284,846; Drug discrimination; Feeding; Flumazenil; Pharmacokinetics; Triazolam; Zaleplon; Zolpidem 61, 55
- Self-administration;** Cocaine; GBR 12909; Phentermine; Progressive ratio; Pharmacotherapy; Abuse potential 62, 41
- Self-administration;** D2 agonists; Psychomotor stimulant; Cocaine; Positive reinforcement; Rhesus monkey 64, 209
- Self-administration;** Ethanol; Discrimination; Oral 64, 243
- Self-administration;** Flunitrazepam; Drug discrimination; Rhesus monkey; Pentobarbital-dependent rats 63, 39
- Self-administration;** Tolerance; Opioids; Rhesus monkeys 62, 181
- Self-help;** Smoking cessation; Nicotine replacement; Behavioral treatment; Smoking 64, 35
- Sensation seeking;** Adolescents; Cigarette use; Disinhibition; Marijuana use 62, 195
- Sensation seeking;** Genetic and environmental influences; Marijuana use; Risk taking; Add health study 62, 57
- Sensitization;** Morphine; Locomotor activity; Rats 62, 83
- Sequence of substance use;** Age; Drug users; Opiates; Heroin 64, 105
- Serotonin antagonist;** Pharmacotherapy; Ritanserin; Cocaine dependence; Treatment 61, 183
- Serotonin;** Cocaine withdrawal; Prolactin; Cortisol; Dopamine 64, 63
- Services;** Cocaine dependence; Treatment intensity; Psychosocial treatment; Outpatient; Day hospital 61, 145
- Services research;** Intravenous drug use; Utilization; Complications 64, 117
- Sex;** Opioid; Morphine; Gender; Behavior; Human 63, 23
- Sex partners;** Drug users; Sexual risk behaviors; HIV 64, 97
- Sexually transmitted disease;** Hepatitis C; Hepatitis B; Methadone; Injection drug users 61, 211
- Sexual risk behaviors;** Drug users; Sex partners; HIV 64, 97
- Sleep problems;** Adolescent; Insomnia; Alcohol; Tobacco; Drug abuse 64, 1
- Smoking cessation;** Self-help; Nicotine replacement; Behavioral treatment; Smoking 64, 35
- Smoking;** Smoking cessation; Self-help; Nicotine replacement; Behavioral treatment 64, 35
- Social class;** Ecstasy consumption; Prevalence; 18 year-olds 64, 329
- Social phobia;** Co-morbidity; Alcohol use; Alcohol challenge; Laboratory stress 64, 219
- Social problems;** Drinking and driving; Alcohol abuse; Alcohol consumption; Traffic accidents 62, 231
- Social relationships;** Methadone patients; Needle sharing; Intravenous drug use; Emotional support 64, 47
- SR 141716A;** Marijuana smoking; Cannabinoid; Δ^9 -THC; Antinociception; Analgesia; Catalepsy; Hypothermia 63, 107
- SSRI;** Alcohol; Prolactin; Fenfluramine 63, 263
- Stimulant;** Methamphetamine; Cocaine; Treatment; HIV 62, 91
- Stimulants;** Injection drug use; Substance abuse treatment; Psychological symptoms 64, 165
- Stress;** Medical students; Pre-registration house officers; Alcohol; Illicit drugs 64, 265
- Subjective effects;** Cocaine; Pharmacotherapy; Flupenthixol; Cardiovascular effects; Pharmacokinetic effects 64, 271
- Subjective effects;** Hallucinogen Rating Scale (HRS); Immediate versus delayed retrospective assessment; Reliability; Convergent analysis 62, 215
- Subjective effects;** Nitrous oxide; Choice; Reinforcing effects; Abuse liability; Inhalants; Human 64, 85
- Subjective response;** Depressive symptoms; Depression; Cocaine; Physiological response 63, 131
- Sublingual;** Buprenorphine; Naloxone; Opiate withdrawal; Pharmacokinetics 61, 85
- Subsequent flashbacks;** Methamphetamine psychosis; Susceptibility; Noradrenergic hyperactivity; 3-Methoxytyramine; Distressing situations 64, 133

- Substance abuse and dependence:** Diagnosis; CIDI-SAM; Physiological dependence; Nosology **61**, 237
- Substance abuse:** Antisocial; Treatment outcome; Gender; Outpatient **61**, 23
- Substance abuse:** Gambling; Impulsivity **63**, 29
- Substance abuse:** Injection drug use; Syringe exchange programs; HIV prevention; Treatment **62**, 225
- Substance abuse:** Opiate users; Maintenance treatments; Epidemiological survey; Harm reduction policies **61**, 281
- Substance abuse treatment:** Injection drug use; Stimulants; Psychological symptoms **64**, 165
- Substance dependence:** Contingency management; Inpatient detoxification; Outpatient aftercare; Treatment compliance **61**, 137
- Substance misuse:** Cocaine; Epidemiological methods; Sampling; Brazil **63**, 79
- Substance-related disorders:** Cannabis; Epidemiologic studies; Survival analysis; Natural history **64**, 123
- Substance-related disorders:** Epidemiology; Aggression; Delinquent behavior; Conduct disorder **63**, 245
- Substance-related disorders:** Helplines; Therapy **62**, 191
- Substance use diagnosis:** Outpatient treatment; Gender; Ethnicity; Employment status; Attendance **62**, 9
- Substance use disorder:** Liability; Puberty; Adolescence; Affective, cognitive, and behavioral dysregulation; Neuroadaptation **61**, 3
- Substance Use:** Gay and Bisexual Men; Young; Prevalence; Correlates **61**, 105
- Survey:** Cocaine; Longitudinal; Marijuana; Methodology **62**, 239
- Survival analysis:** Substance-related disorders; Cannabis; Epidemiologic studies; Natural history **64**, 123
- Susceptibility:** Methamphetamine psychosis; Subsequent flashbacks; Noradrenergic hyperactivity; 3-Methoxytyramine; Distressing situations **64**, 133
- Switzerland:** Alcohol Use Disorders Identification Test (AUDIT); Frequency of drinking; Psychometric analysis; Confirmatory factor analysis **64**, 151
- Sydney:** Injection sites; Drug users; Health **62**, 77
- Syringe exchange programs:** Injection drug use; Substance abuse; HIV prevention; Treatment **62**, 225
- Take-homes:** Methadone; Contingency management; Opiates; Cocaine **62**, 69
- Technology transfer:** Contingency management; Performance feedback; Incentives; Performance management; Drug treatment counselors **63**, 179
- A⁹-THC:** Marijuana smoking; Cannabinoid; SR 141716A; Antinociception; Analgesia; Catalepsy; Hypothermia **63**, 107
- Therapy:** Helplines; Substance-related disorders **62**, 191
- Time perception:** Antisocial personality disorder; Cocaine dependence; Contingent negative variation; Evoked potentials; Conduct disorder; EEG **63**, 87
- Time-trends:** HIV; Injection drug users; Risk reduction; Epidemiology **61**, 315
- T-lymphocyte:** Mu-receptor; Morphine; Mitogen; Gene induction **62**, 131
- Tobacco:** Adolescent; Sleep problems; Insomnia; Alcohol; Drug abuse **64**, 1
- Tobacco:** Cannabis; Comorbidity; Drug use; Population; Alcohol **64**, 319
- Tolerance:** Opioids; Rhesus monkeys; Self-administration **62**, 181
- Toxicology:** Heroin; Morphine; Death; Demographics **61**, 123
- Traffic accidents:** Drinking and driving; Alcohol abuse; Alcohol consumption; Social problems **62**, 231
- Treatment:** Pharmacotherapy; Ritanserin; Cocaine dependence; Serotonin antagonist **61**, 183
- Treatment:** Buprenorphine; Heroin dependence; Human; Opioid withdrawal **64**, 111
- Treatment:** Cocaine; Assessment; Follow-up **62**, 19
- Treatment compliance:** Substance dependence; Contingency management; Inpatient detoxification; Outpatient aftercare **61**, 137
- Treatment:** Craving; Methamphetamine; Relapse **63**, 269
- Treatment:** Fluoxetine; Cocaine; Depression; Dual-diagnosis **63**, 207
- Treatment:** Injection drug use; Substance abuse; Syringe exchange programs; HIV prevention **62**, 225
- Treatment intensity:** Cocaine dependence; Psychosocial treatment; Outpatient; Day hospital; Services **61**, 145
- Treatment:** Methamphetamine; Cocaine; Stimulant; HIV **62**, 91
- Treatment outcome:** Antisocial; Substance abuse; Gender; Outpatient **61**, 23
- Treatment outcome:** Cocaine dependence; Cocaine use; Urine test **62**, 1
- Treatment outcome:** Heroin addiction; Family history; Genetics; Methadone; Maintenance **61**, 261
- Treatment outcome:** Methadone; Personality disorders; Psychiatric diagnosis; Comorbidity **61**, 271
- Treatment outcome:** Novelty seeking; Anti-social personality disorder; Buprenorphine; Heroin dependence; Poly-drug use; Contingency management **61**, 287
- Treatment:** Pregnancy; Buprenorphine; Opioid dependence; Neonatal abstinence syndrome; Perinatal addiction **63**, 97

- Triazolam:** Abuse potential; Benzodiazepine; CL 284846; Dependence; Feeding; Zaleplon **61**, 69
- Triazolam:** Abuse potential; CL 284,846; Drug discrimination; Feeding; Flumazenil; Pharmacokinetics; Self-administration; Zaleplon; Zolpidem **61**, 55
- Triazolam:** Alprazolam; Caffeine; Drug discrimination; Humans; Novel-response procedure; Zolpidem **61**, 249
- Tropanes:** Tyrosine hydroxylase; Catecholamines; Cocaine; Mesolimbic pathway **61**, 15
- Twins:** Alcohol dependence; Genetic; Illicit drug dependence; Post-traumatic stress disorder; Veterans **61**, 95
- Type I/II-Type A/B:** Alcoholic subtype; Cluster analysis; DSM-IV alcohol dependence **63**, 51
- Tyrosine hydroxylase:** Catecholamines; Cocaine; Mesolimbic pathway; Tropans **61**, 15
- U50,488:** HIV/AIDS; κ -Opioid receptors; Immunobiology; Macrophages; RANTES **62**, 149
- Urine test:** Cocaine dependence; Cocaine use; Treatment outcome **62**, 1
- Use:** Abuse; Cannabis; Cohort; Dependence; Gender; Longitudinal study **64**, 347
- U-shaped drinking curve:** Alcohol use; HMO alcohol costs; Drinking patterns and costs **64**, 181
- Utilization:** Intravenous drug use; Complications; Services research **64**, 117
- Veterans:** Alcohol dependence; Genetic; Illicit drug dependence; Post-traumatic stress disorder; Twins **61**, 95
- Vietnam veterans:** Opiate abuse; Mortality; Early predictors; Follow-up **64**, 309
- Volatile solvents:** Inhalants; Nosology; Diagnostic concordance **61**, 223
- Withdrawal:** Anesthesia; Naltrexone; ACTH; Cortisol; Craving **61**, 163
- 18 year-olds:** Ecstasy consumption; Prevalence; Social class **64**, 329
- Young:** Gay and Bisexual Men; Substance Use; Prevalence; Correlates **61**, 105
- Zaleplon:** Abuse potential; Benzodiazepine; CL 284846; Dependence; Feeding; Triazolam **61**, 69
- Zaleplon:** Abuse potential; CL 284,846; Drug discrimination; Feeding; Flumazenil; Pharmacokinetics; Self-administration; Triazolam; Zolpidem **61**, 55
- Zidovudine:** Human immunodeficiency virus; Indinavir; Naloxone; Naltrexone **64**, 257
- Zolpidem:** Abuse potential; CL 284,846; Drug discrimination; Feeding; Flumazenil; Pharmacokinetics; Self-administration; Triazolam; Zaleplon **61**, 55
- Zolpidem:** Alprazolam; Caffeine; Drug discrimination; Humans; Novel-response procedure; Triazolam **61**, 249